Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

Extensive data on immediate and extended release exenatide can be "leveraged and applied" to speed development of a once-monthly injectable, which is ready for Phase III.

You may also be interested in...

Amylin’s Bydureon Approval: How Does It Sit With Novo Nordisk?

Sponsor of the leading GLP-1 agonist, Victoza, sees the launch of the long-acting competitor from Amylin as having a class-wide impact, drawing more patients to GLP-1s – and it thinks that it can stave off the once-weekly contender.

Pressure Mounts For Amylin As Bydureon PDUFA Approaches

With declining sales of Byetta, Amylin has staked its near-term future on the performance of Bydureon, a long-acting formulation of the active ingredient in Byetta.

With Lilly Out, Amylin’s Future Is Tied To Bydureon

With the unwinding of its once-lucrative nine-year partnership with Eli Lilly, Amylin Pharmaceuticals now carries all the risk – and all the reward – of its exenatide franchise for diabetes. With sole ownership of its exenatide franchise, Amlyin now has the freedom to seek a lucrative partnership or opt to sell the company outright to a large pharma seeking an edge in a growing diabetes market.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts